Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines (Q26829316)

Fredrick M. Abrahamian

series ordinal

2

1 reference

Frank LoVecchio

series ordinal

3

1 reference

David A. Talan

series ordinal

4

1 reference

language of work or name

1 reference

June 2013

1 reference

Journal of Emergency Medicine

published in

1 reference

volume

44

1 reference

page(s)

e397-412

1 reference

issue

6

1 reference

Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Community-associated methicillin-resistant Staphylococcus aureus: incidence, clinical presentation, and treatment decisions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Board-certified emergency physicians' treatment of skin and soft tissue infections in the community-acquired methicillin-resistant Staphylococcus aureus era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Cellulitis: definition, etiology, and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

United States resistance surveillance results for linezolid (LEADER Program for 2007).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010)

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Management of skin and soft-tissue infections in the emergency department

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

High-dose daptomycin in documented Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Linezolid: a review of safety and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Outpatient parenteral anti-infective therapy for skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Waves of resistance: Staphylococcus aureus in the antibiotic era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Thrombocytopenia associated with linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Three-year surveillance of community-acquired Staphylococcus aureus infections in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Limitations of vancomycin in the management of resistant staphylococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Microbiology of antibiotic resistance in Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Meeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Outpatient parenteral antimicrobial therapy today

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Hospitalist to home: outpatient parenteral antimicrobial therapy at an academic center

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Skin and soft tissue infections: the new surgical infection society guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Excess deaths associated with tigecycline after approval based on noninferiority trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Acute renal insufficiency during telavancin therapy in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Emergency department treatment failures for skin infections in the era of community-acquired methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Zoonotic Chlamydophila psittaci infections from a clinical perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Clinical outcomes with daptomycin: a post-marketing, real-world evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Emergency management of pediatric skin and soft tissue infections in the community-associated methicillin-resistant Staphylococcus aureus era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Resistance to linezolid caused by modifications at its binding site on the ribosome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Resistance studies with daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Hematologic effects of linezolid: summary of clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Tissue penetration of telavancin after intravenous administration in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Detection of methicillin-resistant Staphylococcus aureus (MRSA) in specimens from various body sites: performance characteristics of the BD GeneOhm MRSA assay, the Xpert MRSA assay, and broth-enriched culture in an area with a low prevalence of MRSA

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Cutaneous community-associated methicillin-resistant staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Ambulatory use of parenteral antibacterials: contemporary perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Methicillin-resistant Staphylococcus aureus in community-acquired skin infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Trends in US hospital admissions for skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021

Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.JEMERMED.2012.11.050

7 January 2021